Armata Pharmaceuticals, Inc. 8-K

What Happened

• Armata Pharmaceuticals (ARMP) announced that on May 12, 2026 it entered into a Credit and Security Agreement with Innoviva Strategic Opportunities LLC (a wholly owned subsidiary of principal shareholder Innoviva, Inc.) providing a $25.0 million secured term loan. The loan carries a 14.0% annual interest rate and matures on January 11, 2029. The Company furnished a related press release on May 13, 2026 (Exhibit 99.1) that also announced its financial results for the three months ended March 31, 2026.

Key Details

• Loan amount: $25.0 million term facility with Innoviva Strategic Opportunities LLC.
• Interest and maturity: 14.0% per annum; maturity date January 11, 2029.
• Security and guarantees: Repayment guaranteed by Armata’s domestic subsidiaries; loan is secured by substantially all assets of the Company and subsidiary guarantors.
• Covenants and defaults: Agreement includes customary affirmative/negative covenants (financial reporting, limits on indebtedness, liens, investments, distributions, mergers/acquisitions, collateral and fundamental changes) and customary events of default (payment defaults, breaches, loss/impairment of collateral, bankruptcy/insolvency, material adverse effect, and a material deviation from the Company’s operating budget).

Why It Matters

• Liquidity and obligations: The $25M loan provides near-term financing and increases liquidity but creates a multi-year repayment obligation and a material interest expense (14% annually).
• Collateral and covenant risk: Because the loan is secured by substantially all assets and guaranteed by domestic subsidiaries, the Company and those subsidiaries face restrictions and potential loss of assets if covenants are breached or a default occurs.
• Reporting: Armata disclosed its Q1 2026 results in the same press release (Exhibit 99.1); investors should review that press release and the full credit agreement (Exhibit 10.1) for detailed financial figures and the complete terms.